Ranolazine: A Contemporary Review

Ranolazine, a piperazine derivative sold under the trade name Ranexa, is a well‐tolerated medication that selectively inhibits the late sodium current. Additionally, ranolazine has beneficial metabolic properties and does not affect heart rate or blood pressure. Ranolazine is currently approved in

• Publication year

  2016

• Venue

  Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/JAHA.116.003196PMID 26979079PMCID 4943285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.

  2016influential reference
• Coronary microvascular dysfunction, microvascular angina, and treatment strategies.

  2015cited by this paper
• The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation Mechanistic and Therapeutic Synergism

  2015cited by this paper
• Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN‐TIMI 36 Trial

  2015cited by this paper
• Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries

  2015cited by this paper
• A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve

  2015influential reference
• Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes

  2015cited by this paper
• Ranolazine: Drug overview and possible role in primary microvascular angina management.

  2015influential reference
• Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study.

  2015cited by this paper
• Effects of Ranolazine on Noninvasive Coronary Flow Reserve in Patients with Myocardial Ischemia But without Obstructive Coronary Artery Disease

  2015influential reference
• Abstract 13387: Effect of Ranolazine on the Incidence of Atrial Fibrillation Following Cardiac Surgery

  2015cited by this paper
• Antiarrhythmic properties of ranolazine: A review of the current evidence.

  2015cited by this paper
• Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery.

  2014cited by this paper
• Health Care Provider Management of Patients With Type 2 Diabetes Mellitus: Analysis of Trends in Attitudes and Practices

  2014cited by this paper
• ANGINA PREVALENCE AND CHARACTERISTICS IN CORONARY ARTERY DISEASE PATIENTS WITH AND WITHOUT DIABETES

  2014cited by this paper
• The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.

  2014influential reference
• Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation.

  2014cited by this paper
• Ranolazine Enhances the Antiarrhythmic Activity of Amiodarone by Accelerating Conversion of New-Onset Atrial Fibrillation After Cardiac Surgery

  2013cited by this paper
• ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology

  2013cited by this paper
• Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II.

  2013cited by this paper
• Coronary microvascular dysfunction.

  2013cited by this paper
• Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score

  2013cited by this paper
• Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.

  2013influential reference
• Long-term survival in patients with refractory angina.

  2013cited by this paper
• Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).

  2013cited by this paper
• Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I

  2013cited by this paper
• The arrhythmogenic consequences of increasing late INa in the cardiomyocyte.

  2013cited by this paper
• 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

  2013cited by this paper
• 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2012cited by this paper
• 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2012cited by this paper
• The Use of Ranolazine to Facilitate Electrical Cardioversion in Cardioversion‐Resistant Patients: A Case Series

  2012cited by this paper
• 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physi

  2012cited by this paper
• 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass

  2012cited by this paper
• Faculty Opinions recommendation of 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2012cited by this paper
• Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial

  2012cited by this paper
• Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.

  2011cited by this paper
• 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2011cited by this paper
• Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting.

  2011cited by this paper
• Ranolazine: a new approach to treating an old problem.

  2010cited by this paper
• Long-term prognosis of patients with cardiac syndrome X.

  2010cited by this paper
• Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement.

  2009cited by this paper
• A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.

  2009cited by this paper
• The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation

  2008cited by this paper
• Late sodium current inhibition as a new cardioprotective approach.

  2008cited by this paper
• Positive shifts in the perceived meaning of cardiac pain following a psychoeducation program for chronic stable angina.

  2007cited by this paper
• Coronary Microvascular Dysfunction

  2007cited by this paper
• Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.

  2007cited by this paper
• Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).

  2007cited by this paper
• Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions.

  2006cited by this paper
• Clinical Pharmacokinetics of Ranolazine

  2006influential reference
• Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine

  2006cited by this paper
• Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts.

  2006cited by this paper
• Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.

  2006influential reference
• Ranolazine in the management of chronic stable angina.

  2006cited by this paper
• Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.

  2005cited by this paper
• Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties

  2004cited by this paper
• Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

  2004cited by this paper
• Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

  2004influential reference
• ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).

  2004cited by this paper
• Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I

  2003cited by this paper
• Evidence that ranolazine behaves as a weak β1- and β2-adrenoceptor antagonist in the rat cardiovascular system

  2001cited by this paper
• Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system.

  2001cited by this paper
• A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.

  1999cited by this paper
• Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.

  1996cited by this paper
• Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.

  1994cited by this paper
• Double‐Blind Efficacy and Safet Study of a Novel Anti‐Ischemic Agent, Ranolazine, Versus Placebo in Patients With Chronic Stable Angina Pectoris

  1994influential reference
• Role of Intracellular Na+ in Ca2+ Overload and Depressed Recovery of Ventricular Function of Reperfused Ischemic Rat Hearts Possible Involvement of H+-Na+ and Na+-Ca2+ Exchange

  1989cited by this paper

• Developing a novel aging assessment model to uncover heterogeneity in organ aging and screening of aging-related drugs

  2025cites this paper
• Ranolazine as a therapeutic agent for diabetic cardiomyopathy: reducing endoplasmic reticulum stress and inflammation in type 2 diabetic rat model

  2025cites this paper
• Ranolazine: An Established Anti-Anginal Drug with Emerging Antidiabetic Potential Supported by Preclinical and Clinical Evidence.

  2025cites this paper
• A review on fueling recovery: the role of metabolic modulation in non-obstructive myocardial stunning

  2025cites this paper
• THERAPEUTIC PERSPECTIVES IN THE MANAGEMENT OF PATIENTS WITH CHRONIC CORONARY SYNDROME

  2025cites this paper
• Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly.

  2025cites this paper
• An updated review on therapeutic strategies in coronary microvascular dysfunction.

  2025cites this paper
• Discovery of platelet glycoprotein VI receptor antagonists and their neuroprotective activity: an in silico, in vitro, and in vivo study

  2025cites this paper
• Unraveling the pharmacological and therapeutic potential of Ranolazine beyond antianginal drug use: a new insight

  2025cites this paper
• Optimal Medical Therapy for Stable Ischemic Heart Disease: Focus on Anti-anginal Therapy.

  2024cites this paper
• Complex visual hallucinations associated with ranolazine treatment: a case report.

  2024cites this paper
• Ranolazine toxicity precipitating seizure in the elderly

  2024cites this paper
• Eco-friendly hydrotropic spectrophotometric analysis of ranolazine hydrochloride.

  2024cites this paper
• Ranolazine Unveiled: Rediscovering an Old Solution in a New Light

  2024cites this paper
• Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers

  2024cites this paper
• Unveiling the Longitudinal Journey: 3-Year Follow-up of Women with MINOCA and INOCA in a Specialized Heart Centre

  2024cites this paper
• Strategies for chronic coronary disease: A brief guide for clinicians

  2024cites this paper
• DIGITALIZATION OF THE ELECTROCARDIOGRAM IN THE OPTIMIZATION OF THE TREATMENT OF ACUTE AND CHRONIC CORONARY SYNDROMES WITH THE USE OF RANOLAZINE

  2024cites this paper
• Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials

  2024cites this paper
• The Role of Ranolazine in Heart Failure-Current Concepts.

  2023cites this paper
• Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials

  2023cites this paper
• Amorphous Solid Forms of Ranolazine and Tryptophan and Their Relaxation to Metastable Polymorphs

  2023cites this paper
• Chronic Testosterone Deficiency Increases Late Inward Sodium Current and Promotes Triggered Activity in Ventricular Myocytes from Aging Male Mice.

  2023cites this paper
• Medical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease.

  2023cites this paper
• Multitargeting in cardioprotection: An example of biaromatic compounds

  2023cites this paper
• Novel concepts in the management of angina in coronary artery disease.

  2023cites this paper
• Structural basis for inhibition of the cardiac sodium channel by the atypical antiarrhythmic drug ranolazine

  2023cites this paper
• Conductance Changes of Na+ Channels during the Late Na+ Current Flowing under Action Potential Voltage Clamp Conditions in Canine, Rabbit, and Guinea Pig Ventricular Myocytes

  2023cites this paper
• The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice

  2023cites this paper
• Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis

  2023cites this paper
• Targeting fatty acid metabolism in glioblastoma

  2023cites this paper
• Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis.

  2022cites this paper
• Riluzole and ranolazine application of prostate cancer: Cancer related testicular and liver tissue damage

  2022cites this paper
• Keratolysis exfoliativa-like eruption induced by ranolazine

  2022cites this paper
• Ranolazine rescues the heart failure phenotype of PLN-deficient human pluripotent stem cell-derived cardiomyocytes

  2022cites this paper
• The Canadian Women’s Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women — Chapter 6: Sex- and Gender-Specific Diagnosis and Treatment

  2022cites this paper
• Ziprasidone Induces Rabbit Atrium Arrhythmogenesis via Modification of Oxidative Stress and Sodium/Calcium Homeostasis

  2022cites this paper
• Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine

  2022cites this paper
• Ranolazine - could an antianginal drug be used in stroke prevention?

  2022cites this paper
• Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs

  2022cites this paper
• Pharmacologic modulation of intracellular Na+ concentration with ranolazine impacts inflammatory response in humans and mice

  2022cites this paper
• Ranolazine Counteracts Strength Impairment and Oxidative Stress in Aged Sarcopenic Mice

  2022cites this paper
• Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement.

  2022cites this paper
• Actualización del uso de los fármacos antianginosos en el tratamiento del síndrome coronario crónico: enfoque práctico

  2022cites this paper
• Angina in 2022: Current Perspectives

  2022cites this paper
• Antiarrhythmic drugs and anaesthesia. Part 2: pharmacotherapy.

  2022cites this paper
• A critical appraisal of the pharmacological management of stable angina.

  2021cites this paper
• Comparison of Pharmacokinetics and Safety of Ranolazine PR between Koreans and Caucasians.

  2021cites this paper
• Keratolysis exfoliativa-like eruption induced by ranolazione

  2021cites this paper
• Impact of ranolazine on exercise tolerance and arrhythmias in patients with INOCA

  2021cites this paper
• Coronary Heart Disease and Myocardial Ischemia

  2021cites this paper
• Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning

  2021cites this paper
• A pathophysiological compass to personalize antianginal drug treatment

  2021cites this paper
• Ranolazine Protects the Kidney from Ischemia/Reperfusion Injury in Adult Male Rats by Modulation of Inflammatory and Oxidative Pathways and Suppression of Notch2/Hes1 signaling pathway

  2021cites this paper
• Mechanical effects of ranolazine on normal and diabetic-isolated rat heart

  2021cites this paper
• Ranolazine-induced lipid storage myopathy presenting with respiratory failure and head drop.

  2021cites this paper
• Simultaneous and Trace Level Quantification of Five Potential Genotoxic Impurities in Ranolazine Active Pharmaceutical Ingredient Using LC-MS/MS

  2021cites this paper
• Platelet reactivity in patients with coronary artery disease on treatment with ivabradine and clopidogrel: The PLATIVA study

  2021cites this paper
• An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts

  2021cites this paper
• Neurological complications of cardiovascular drugs.

  2021cites this paper
• Ranolazine for Symptomatic Management of Microvascular Angina.

  2020cites this paper
• MULTIPLE ROLES OF RANOLAZINE BEYOND ANGINA PECTORIS

  2020cites this paper
• Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction—A Systematic Review and Meta-analysis of Randomized Trials

  2020cites this paper
• Cardiovascular toxicity of PI3Kα inhibitors.

  2020cites this paper
• LIPOID SPC-3-Based Coprecipitates for the Enhancement of Aqueous Solubility and Permeability of Ranolazine

  2020cites this paper
• Effect of ranolazine on symptom and quality of life in patients with angina in the absence of obstructive coronary artery disease: A case control study.

  2020cites this paper
• Ranolazine treatment for refractory angina in a patient with Hutchinson-Gilford progeria syndrome and end stage aortic stenosis

  2020cites this paper
• Challenges and Opportunities for Therapeutic Targeting of Calmodulin Kinase II in Heart

  2020cites this paper
• Stable Ischemic Heart Disease

  2020cites this paper
• Potential Beneficial Effects of Vitamin D in Coronary Artery Disease

  2019cites this paper
• Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA‐MB‐231 breast cancer cells: Effects of combination with ranolazine

  2019cites this paper
• De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.

  2019cites this paper
• The Search for Disease-Modifying Therapies in Pulmonary Hypertension

  2019cites this paper
• Noninvasive Assessment of Coronary Flow Reserve Before and After Ranolazine Administration: Does It Improve in Our Real Patients?

  2018cites this paper
• Indian Consensus on OPtimal Treatment of Angina (OPTA ).

  2018cites this paper
• Treatment of Angina: Where Are We?

  2018cites this paper
• Ranolazine Prevents Levosimendan-Induced Atrial Fibrillation

  2018cites this paper
• Digitalis Promotes Ventricular Arrhythmias in Flecainide- and Ranolazine-Pretreated Hearts

  2018cites this paper
• Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again

  2018cites this paper
• Patient specific Long QT syndrome type 3 cardiomyocytes can be used for clinical drug safety assessments

  2018cites this paper
• Impact of ranolazine on ventricular arrhythmias – A systematic review

  2018cites this paper
• Role of ranolazine in the management of refractory angina

  2018cites this paper
• Expert consensus document: A 'diamond' approach to personalized treatment of angina

  2018cites this paper
• Non-ST elevation acute coronary syndrome in women and the elderly: recent updates and stones still left unturned

  2018cites this paper
• Recent Developments in Sex-Related Differences in Presentation, Prognosis, and Management of Coronary Artery Disease.

  2018cites this paper
• Efficacy and Safety of Ranolazine in Diabetic Patients: A Systematic Review and Meta-analysis

  2018cites this paper
• Ranolazine treatment in the heterogeneous symptomatic stable coronary artery disease population

  2018cites this paper
• Experimentelle Untersuchungen zur proarrhythmischen Wirkung des Kalzium-Sensitizers Levosimendan sowie möglicher protektiver Therapieoptionen

  2017influential citation
• Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.

  2017cites this paper
• Ranolazine for Refractory Angina in a Heart Transplant Recipient With Cardiac Allograft Vasculopathy

  2017cites this paper
• The coronary sinus reducer: clinical evidence and technical aspects

  2017cites this paper
• Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure

  2017cites this paper
• Shared Genetic Risk Factors of Intracranial, Abdominal, and Thoracic Aneurysms

  2016cites this paper
• Elongation of Long‐Chain Fatty Acid Family Member 6 (Elovl6)‐Driven Fatty Acid Metabolism Regulates Vascular Smooth Muscle Cell Phenotype Through AMP‐Activated Protein Kinase/Krüppel‐Like Factor 4 (AMPK/KLF4) Signaling

  2016cites this paper
• Percutaneous Pulmonary Valve Implantation Alters Electrophysiologic Substrate

  2016cites this paper
• Subsequent Shockable Rhythm During Out‐of‐Hospital Cardiac Arrest in Children With Initial Non‐Shockable Rhythms: A Nationwide Population‐Based Observational Study

  2016cites this paper
• International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives

  2016cites this paper
• Predictors and Long‐Term Clinical Impact of Acute Stent Malapposition: An Assessment of Dual Antiplatelet Therapy With Drug‐Eluting Stents (ADAPT‐DES) Intravascular Ultrasound Substudy

  2016cites this paper
• Nonsustained Atrial Fibrillation in Ischemic Stroke Patients and Stroke‐Free Controls From the Perspective of Stroke Pathophysiology

  2016cites this paper
• Patent Foramen Ovale With Atrial Septal Aneurysm Is Strongly Associated With Migraine With Aura: A Large Observational Study

  2016cites this paper